It's not always clear what causes bladder cancer. Bladder cancer has been linked to smoking, a parasitic infection, radiation and chemical exposure.
Bladder cancer develops when cells in the bladder begin to grow abnormally. Rather than grow and divide in an orderly way, these cells develop mutations that cause them to grow out of control and not die. These abnormal cells form a tumor.
Types of bladder cancer
Different types of cells in your bladder can become cancerous. The type of bladder cell where cancer begins determines the type of bladder cancer. Your bladder cancer type determines which treatments may work best for you.
Types of bladder cancer include:
- Transitional cell carcinoma. Transitional cell carcinoma occurs in the cells that line the inside of your bladder. Transitional cells expand when your bladder is full and contract when your bladder is empty. These same cells line the inside of your ureters and your urethra, and tumors can form in those places as well. Transitional cell carcinoma is the most common type of bladder cancer in the United States.
- Squamous cell carcinoma. Squamous cells appear in your bladder in response to infection and irritation. Over time they can become cancerous. Squamous cell bladder cancer is rare in the United States. It's more common in parts of the world where a certain parasitic infection (schistosomiasis) is a prevalent cause of bladder infections.
- Adenocarcinoma. Adenocarcinoma begins in cells that make up mucus-secreting glands in the bladder. Adenocarcinoma of the bladder is rare in the United States.
Some bladder cancers include more than one type of cell.
June 30, 2015
- What you need to know about bladder cancer. National Cancer Institute. http://www.cancer.gov/publications/patient-education/wyntk-bladder-cancer. Accessed May 4, 2015.
- Bladder cancer treatment (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/bladder/healthprofessional. Accessed May 4, 2015.
- Niederhuber JE, et al., eds. Bladder cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed May 4, 2015.
- Bladder and other urothelial cancers screening (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/screening/bladder/healthprofessional. Accessed May 4, 2015.
- Bladder cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 4, 2015.
- Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis): 2007 update. Linthicum, Md.: American Urological Association. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bc. Accessed May 4, 2015.
- Wein AJ, et al., eds. Urothelial cancer. In: Campbell-Walsh Urology. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. http://www.clinicalkey.com. Accessed May 4, 2015.
- FDA drug safety communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed May 5, 2015.
- Knoedler J, et al. Organ-sparing surgery in urology: Partial cystectomy. Current Opinion Urology. 2015;25:111.
- Smith ND, et al. The RAZOR (randomized open vs. robotic cystectomy) trial: Study design and trial update. British Journal of Urology International. 2015;115:198.
- Cook AJ. Decision Support System. Mayo Clinic, Rochester, Minn. Dec. 17, 2014.
- Castle EP (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. June 11, 2015.